Tirzepatide vs Semaglutide:
An Honest Breakdown

You've probably heard both names — Wegovy and Zepbound — and you may be wondering which one is better, which one is safer, and why your insurance seems to have a strong opinion about which one you should use. These are fair questions, and the answers are more nuanced than most of what you'll find online.

Here's what I can tell you as a PA-C who prescribes both: both medications work. Both are real, evidence-based treatments for obesity. Tirzepatide (Zepbound) tends to produce more weight loss on average and is generally better tolerated — but it's less reliably covered by insurance and often more expensive out of pocket. Semaglutide (Wegovy) is the medication most insurance plans cover first, and it works very well for the majority of patients who take it with proper guidance. Neither is "bad." There's a lot of fear-mongering online about both of these medications, and by the end of this article I'm hoping to clear some of that up.

Let's go through this systematically.

How each medication works

The core difference is that tirzepatide works on two hormone receptors (GLP-1 and GIP) while semaglutide works on one (GLP-1). This dual mechanism is why tirzepatide tends to produce more weight loss — but it also means the two medications have some different side effect profiles and drug interactions, which matters in specific situations.

What the head-to-head data actually shows

For a long time, comparing these two medications meant comparing results across separate trials with different study designs and patient populations — which isn't a fair comparison. That changed in May 2025, when the first direct head-to-head trial (SURMOUNT-5) was published in the New England Journal of Medicine. And just days before this article was published, the landscape shifted again: on March 19, 2026, the FDA approved Wegovy HD — semaglutide 7.2 mg — based on the STEP UP trial, which showed mean weight loss of 20.7% at 72 weeks.

At the standard 2.4 mg dose, tirzepatide produced about 6.5 percentage points more weight loss than semaglutide in SURMOUNT-5, and outperformed semaglutide on every secondary endpoint including waist circumference and milestone weight loss targets. You may have heard that semaglutide produces closer to 15% weight loss — and that's also accurate. The individual STEP trials (semaglutide vs placebo) showed approximately 14.9–15% weight loss; the 13.7% figure comes specifically from SURMOUNT-5, where the patient population was somewhat different and both drugs were compared head-to-head. Both numbers are real — they just come from different study designs. However, Wegovy HD at 7.2 mg changes this picture significantly — achieving 20.7% mean weight loss in STEP UP, which is comparable to tirzepatide's 20.2% in SURMOUNT-5. It's important to note these are different trials with different designs, so a direct comparison isn't perfect. But the emergence of Wegovy HD means semaglutide now has a higher-dose option that can compete with tirzepatide's efficacy for patients who tolerate the lower dose but need greater weight loss.

Real-world studies confirm that both medications deliver meaningful results outside of trial conditions. A 2025 retrospective cohort study found that patients on tirzepatide lost about 16.5% of body weight at one year, compared to 14.1% for semaglutide — somewhat lower than trials as expected in real-world settings, but consistent with tirzepatide's efficacy edge at standard doses.

Side effect comparison

Both medications share a similar side effect profile — primarily gastrointestinal — because both slow gastric emptying. The differences are in degree, not category.

In clinical practice, tirzepatide is generally better tolerated — particularly for nausea and vomiting — which is one reason some patients and providers prefer it. But this doesn't mean Wegovy isn't tolerable. The majority of people on semaglutide manage side effects well, especially with proper dose escalation, dietary adjustments, and guidance from their provider.

The fear-mongering about Wegovy — what's real and what isn't

There's a significant amount of negative content about Wegovy online — social media posts, forums, and even some news coverage that frames it as dangerous, poorly tolerated, or inferior in ways that go well beyond what the evidence shows. As someone who prescribes both medications, I want to address this directly.

What is true: Semaglutide does produce more GI side effects on average than tirzepatide, as the SURMOUNT-5 data confirms. Some patients have a difficult time tolerating it, particularly at higher doses. A small percentage (around 5–6%) discontinue because of GI side effects — and that's worth taking seriously.

What is not true: That Wegovy is dangerous, that most people can't tolerate it, or that it's a medication to avoid. The large STEP clinical trial program — involving thousands of patients — established semaglutide as safe and effective. The majority of patients tolerate it well when dosed and managed properly. It also has a longer track record than tirzepatide, having been on the market for obesity since 2021.

Who is each medication better for?

Birth control — something most patients haven't been told

This is one of the most important sections in this article, because the interaction between tirzepatide and oral birth control pills is clinically significant and very frequently goes undiscussed at the time of prescribing.

This distinction can make a real difference for your medication choice. If you are on the pill and want to continue on it without additional methods, semaglutide is the more straightforward option. If tirzepatide is the right medication for other reasons, the solution is switching to a non-oral contraceptive method. Your provider should be discussing this with you before starting tirzepatide.

Mood changes and mental health — what we know

This topic has generated significant concern over the past few years, so I want to give you an honest, up-to-date picture rather than minimizing legitimate questions or amplifying unsupported fears.

What the FDA concluded

In January 2026, after a comprehensive meta-analysis of clinical trial data across GLP-1 drug development programs, the FDA announced that it found no increased risk of suicidal ideation or behavior associated with GLP-1 receptor agonist medications — including both semaglutide and tirzepatide. As a result, the FDA requested the removal of the suicidal ideation warning that had previously appeared on the labels of Wegovy, Saxenda, and Zepbound. This was based on a large study of over 2.2 million patients.

This is reassuring news, and the fear that these medications cause suicidal thinking is not supported by the current body of evidence.

What still warrants attention

That said, the FDA conclusion specifically addressed suicidal ideation. A separate and important clinical reality remains: patients with a pre-existing history of anxiety or depression can experience worsening of those symptoms while on GLP-1 medications. This is not the same as a causal relationship, and the mechanisms are not fully understood, but it has been observed in clinical practice and in pharmacovigilance data.

An unexpected benefit: reduced cravings and addictive behaviors

One of the more surprising things patients report on GLP-1 medications — and what clinical data is increasingly confirming — is a reduction in cravings for alcohol, nicotine, and other substances. This isn't just anecdote. Several observational and pharmacovigilance studies have found signals suggesting GLP-1 receptor agonists may reduce alcohol consumption and alcohol-related events, and researchers believe this is related to GLP-1's action on reward pathways in the brain.

In my own clinical practice, I hear this regularly from patients — often unprompted. People describe drinking less alcohol, sometimes significantly, without consciously trying to. Some notice reduced interest in highly palatable or impulsive eating behaviors that had previously felt compulsive. The mechanism is not fully understood and clinical trials specifically investigating GLP-1s for alcohol use disorder are ongoing, but the signal is consistent enough that it's worth knowing about.

Cost and insurance coverage

Compounded semaglutide and tirzepatide

During the shortage period of 2023–2025, compounded versions of both semaglutide and tirzepatide were widely available from compounding pharmacies. The landscape has changed significantly as of 2025–2026.

The FDA has confirmed that both semaglutide and tirzepatide shortages have been resolved, which means most compounded versions are no longer legally permissible under federal law — compounding is allowed only when FDA-approved versions are unavailable. Many compounding pharmacies have ceased or significantly reduced production of these medications. For a detailed breakdown of the current regulatory status, see our GLP-1 Medication Guide.

The bottom line

Both tirzepatide and semaglutide are excellent, evidence-based treatments for obesity. Tirzepatide produces more weight loss on average — this is now established by a rigorous head-to-head trial. It is also generally better tolerated from a GI standpoint. But it's covered less reliably by insurance, it has a specific interaction with oral birth control that semaglutide doesn't, and it has a shorter market history.

Semaglutide is a fantastic medication that works well for the vast majority of people who take it with proper guidance. The online fear-mongering about Wegovy does not reflect an accurate picture of the evidence. For many patients, it will be the right first medication — either because it's what their insurance covers, because of the cardiovascular indication, or because of the birth control consideration.

The best medication is the one you can actually access, afford, and stay on. A medication that produces 20% weight loss on a clinical trial population means nothing if you can't fill the prescription. Work with your provider to find the option that fits your clinical picture, your insurance, and your life.

Note for providers